Nirmidas Biotech, Inc.
1 Article found
Nirmidas Biotech, Inc. articles
Abstract
Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between vaccines. Here we performed a prospective pilot study of 71 previously COVID-19 free subjects u
Jul. 2, 2021
Kevin P. Bliden;Tiancheng Liu;Deepika Sreedhar;Jessica Kost;Jessica Hsiung;Su Zhao;Dingying Shan;Abira Usman;Naval Walia;Alastair Cho;Christophe Jerjian;Udaya S. Tantry;Paul A. Gurbel;Meijie Tang
